ReviewACS pharmacology & translational science2020
The Brain-Heart Axis: Alzheimer's, Diabetes, and Hypertension.
Review in ACS pharmacology & translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Repetitive transcranial magnetic stimulation ameliorates myocardial injury in vascular dementia via renin-angiotensin system modulation.Neuroreport · 2025Article
- Translational disease modeling of peripheral blood identifies type 2 diabetes biomarkers predictive of Alzheimer's disease.NPJ systems biology and applications · 2025Article
- Causal associations between hypertension and abnormal brain cortical structures: Insights from a bidirectional Mendelian randomization study.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Effects of physical multimorbidity on cognitive decline trajectories among adults aged 50 years and older with different wealth status: a 17-year population-based cohort study.Global mental health (Cambridge, England) · 2024Article
- Sympathetic and parasympathetic central autonomic networks.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Depression as a cardiovascular disorder: central-autonomic network, brain-heart axis, and vagal perspectives of low mood.Frontiers in network physiology · 2023Article
- Integrating Comorbidity Knowledge for Alzheimer's Disease Drug Repurposing using Multi-task Graph Neural Network.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2023Article
- Diabetes and its Complications.ACS pharmacology & translational science · 2022Article
- Markers of kidney function, genetic variation related to cognitive function, and cognitive performance in the UK Biobank.BMC nephrology · 2022Article
- Oestrogenic Regulation of Mitochondrial Dynamics.International journal of molecular sciences · 2022Review
- Cognition impairment and risk of subclinical cardiovascular disease in older adults: The atherosclerosis risk in communities study.Frontiers in aging neuroscience · 2022Article
- Hybrid total-body pet scanners-current status and future perspectives.European journal of nuclear medicine and molecular imaging · 2022Review
- Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system.Expert review of neurotherapeutics · 2021Article
- Natriuretic Peptides, Cognitive Impairment and Dementia: An Intriguing Pathogenic Link with Implications in Hypertension.Journal of clinical medicine · 2020Review
- Emerging Leaders in Pharmacology and Translational Science Special Issue Editorial.ACS pharmacology & translational science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting millions worldwide. Currently, there are only four approved treatments for AD, which improve symptoms modestly. AD is believed to be caused by the formation of intercellular plaques and intracellular tangles in the brain, but thus far all new drugs which target these pathologies have failed clinical trials. New research highlights the link between AD and Type II Diabetes (T2D), and some believe that AD is actually a brain specific form of it termed Type III Diabetes (T3D). Drugs which are currently approved for the treatment of T2D, such as metformin, have shown promising results in improving cognitive function and even preventing the development of AD in diabetic patients. Recent studies shed light on the relationship between the brain and cardiovascular system in which the brain and heart communicate with one another via the vasculature to regulate fluid and nutrient homeostasis. This line of research reveals how the brain-heart axis regulates hypertension and diabetes, both of which can impact cognitive function. In this review we survey past and ongoing research and clinical trials for AD, and argue that AD is a complex and systemic disorder which requires comprehensive approaches beyond the brain for effective prevention and/or treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.